Literature DB >> 1233238

Plasma concentration of alpha-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester.

J A Saavedra, J L Reid, W Jordan, M D Rawlins, C T Dollery.   

Abstract

The plasma concentrations of free alpha-methyldopa and methyldopa sulphate conjugate were measured in 7 hypertensive patients with normal renal function following alpha-methyldopa (1 g) orally. Five of these patients subsequently received alpha-methyldopa ethyl ester (250 mg) (methyldopate) intravenously and two further patients received 250 mg of alpha-methyldopa intravenously. After oral administration a large amount of total plasma alpha-methyldopa was present as sulphate conjugate. There were wide interindividual differences in the ratio of free: conjugated alpha-methyldopa in plasma (ratio at 4 hours ranged from 3.73-0.83) suggesting that individual differences in the extent of sulphate conjugation may occur. There was no close correlation between the degree of conjugation and the fall in arterial pressure. At all time intervals examined, plasma concentrations were higher following intravenous alpha-methyldopa than alpha-methyldopate. The plasma concentration of alpha-methyldopa (free and esterified) 60 minutes after i.v. alpha-methyldopate was 1.7+/-0.3 mug/ml while at the same time after the same dose of methyldopa by the same route the mean concentration was 5.9 mug/ml. Although small amounts of sulphate conjugate were detected after i.v. alpha-methyldopate, insignificant quantities of conjugate were found after i.v. alpha-methyldopa. The average fall in mean arterial pressure was 27 mm/Hg following i.v. alpha-methyldopa but only 2.7 mm Hg following alpha-methyldopate. These results suggest that sulphate conjugation of alpha-methyldopa occurs in the gastrointestinal tract during absorption. Hydrolysis of alpha-methyldopa ethyl ester does not appear to be instantaneous and pharmacokinetic differences between the ester and free alpha-methyldopa have been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233238     DOI: 10.1007/bf00562310

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS.

Authors:  R P BUHS; J L BECK; O C SPETH; J L SMITH; N R TRENNER; P J CANNON; J H LARAGH
Journal:  J Pharmacol Exp Ther       Date:  1964-02       Impact factor: 4.030

2.  A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1962-12       Impact factor: 4.030

3.  STUDIES ON THE METABOLISM AND MECHANISM OF ACTION OF METHYLDOPA.

Authors:  A SJOERDSMA; A VENDSALU; K ENGELMAN
Journal:  Circulation       Date:  1963-10       Impact factor: 29.690

4.  The synthesis and hydrolysis of sulfate esters.

Authors:  A B ROY
Journal:  Adv Enzymol Relat Subj Biochem       Date:  1960

5.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

6.  Hypotensive effect of methyldopa in renal failure associated with hypertension.

Authors:  O Stenbaek; E Myhre; E K Brodwall; T Hansen
Journal:  Acta Med Scand       Date:  1972-04

7.  [Pharmacokinetics of alpha-methyldopa in kidney failure].

Authors:  K Schrader; H Brass; D Renner
Journal:  Klin Wochenschr       Date:  1971-12-15

8.  Combined clinical and metabolic study of the effects of alpha-methyldopa on hypertensive patients.

Authors:  L F Prescott; R P Buhs; J O Beattie; O C Speth; N R Trenner; L Lasagna
Journal:  Circulation       Date:  1966-08       Impact factor: 29.690

9.  Metabolism of isoprenaline in dog and man.

Authors:  M E Conolly; D S Davies; C T Dollery; C D Morgan; J W Paterson; M Sandler
Journal:  Br J Pharmacol       Date:  1972-11       Impact factor: 8.739

10.  The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects.

Authors:  W Y Au; L G Dring; D G Grahame-Smith; P Isaac; R T Williams
Journal:  Biochem J       Date:  1972-08       Impact factor: 3.857

View more
  13 in total

1.  Pharmacokinetics of methyldopa in healthy man.

Authors:  O Stenbaek; E Myhre; H E Rugstad; E Arnold; T Hansen
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

2.  Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers.

Authors:  K Róna; K Ary; G Renczes; B Gachályi; G Y Grézal; S Drabant; I Klebovich
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

Review 3.  Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.

Authors:  D E Drayer
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

4.  alpha-Methyldopa, alpha-methyldopamine an alpha-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase.

Authors:  G Mwaluko; R Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of methyldopa.

Authors:  E Myhre; H E Rugstad; T Hansen
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

6.  A study of the transfer of alpha-methyldopa to the human foetus and newborn infant.

Authors:  H M Jones; A J Cummings
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

7.  The effects of desmethylimipramine on the pharmacological actions of alpha methyldopa in man.

Authors:  J L Reid; A J Porsius; C Zamboulis; G Polak; C A Hamilton; C R Dean
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 8.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 9.  Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.

Authors:  Gail D Anderson; Darcy B Carr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment.

Authors:  A G Renwick; V Higgins; K Powers; C L Smith; C F George
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.